282 related articles for article (PubMed ID: 21297955)
1. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
Ellrichmann G; Petrasch-Parwez E; Lee DH; Reick C; Arning L; Saft C; Gold R; Linker RA
PLoS One; 2011 Jan; 6(1):e16172. PubMed ID: 21297955
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.
Lee DH; Gold R; Linker RA
Int J Mol Sci; 2012; 13(9):11783-11803. PubMed ID: 23109883
[TBL] [Abstract][Full Text] [Related]
3. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
Linker RA; Lee DH; Ryan S; van Dam AM; Conrad R; Bista P; Zeng W; Hronowsky X; Buko A; Chollate S; Ellrichmann G; Brück W; Dawson K; Goelz S; Wiese S; Scannevin RH; Lukashev M; Gold R
Brain; 2011 Mar; 134(Pt 3):678-92. PubMed ID: 21354971
[TBL] [Abstract][Full Text] [Related]
4. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
5. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.
Paldino E; Balducci C; La Vitola P; Artioli L; D'Angelo V; Giampà C; Artuso V; Forloni G; Fusco FR
Mol Neurobiol; 2020 Apr; 57(4):1889-1903. PubMed ID: 31879858
[TBL] [Abstract][Full Text] [Related]
7. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
9. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
10. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases.
Majkutewicz I
Eur J Pharmacol; 2022 Jul; 926():175025. PubMed ID: 35569547
[TBL] [Abstract][Full Text] [Related]
13. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
14. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
15. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Wu CH
Clin Interv Aging; 2015; 10():1825-37. PubMed ID: 26609226
[TBL] [Abstract][Full Text] [Related]
16. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.
Gil JM; Leist M; Popovic N; Brundin P; Petersén A
BMC Neurosci; 2004 May; 5():17. PubMed ID: 15134587
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
Alpaugh M; Galleguillos D; Forero J; Morales LC; Lackey SW; Kar P; Di Pardo A; Holt A; Kerr BJ; Todd KG; Baker GB; Fouad K; Sipione S
EMBO Mol Med; 2017 Nov; 9(11):1537-1557. PubMed ID: 28993428
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
[TBL] [Abstract][Full Text] [Related]
19. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
20. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
